UnitedHealth Group Incorporated rose 2.3% to $399.06 on Monday, as technology shares dragged down the wider market and boosted the insurer's defensive profile. The price was quoted at 3:37 p.m. EDT.
UnitedHealth is sacrificing membership to restore margins. The second-quarter medical care ratio improved 270 basis points, but commercial medical-cost growth remains modestly above 11%. The stock's forward multiple therefore prices a recovery that is real, but not yet complete.
| Metric | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $112.0B | $111.6B | +0.4% |
| Operating earnings | $8.0B | $5.2B | +54% |
| Medical care ratio | 86.7% | 89.4% | −270 bp |
| UnitedHealthcare margin | 4.6% | 2.4% | +220 bp |
| Optum margin | 6.2% | 4.6% | +160 bp |
| UHC membership | 48.5M | — | −525K q/q |
| 2026 measure | Jan. 27 | July 16 | Signal |
|---|---|---|---|
| Adjusted EPS | >$17.75 | $19.50–$20.00 | Raised |
| Operating earnings | >$24.0B | >$25.45B | Raised |
| Cash from operations | >$18.0B | ~$24.0B | Raised |
| Share repurchases | ~$2.5B | ≥$5.0B | Doubled |
| Medical care ratio | 88.8% ±50 bp | 88.1% ±25 bp | Improved |
| Firm | Date | Rating | Target |
|---|---|---|---|
| JPMorgan | Jul. 21 | Overweight | $516 |
| Mizuho | Jul. 21 | Outperform | $493 |
| BofA Securities | Jul. 20 | Buy | $512 |
| Wells Fargo | Jul. 2026 | Overweight | $526 |
| Company | Price | Day | Trailing P/E |
|---|---|---|---|
| UnitedHealth | $399.06 | +2.29% | 25.6× |
| Elevance Health | $402.56 | +0.50% | 17.8× |
| CVS Health | $93.31 | +0.31% | 24.6× |
| The Cigna Group | $278.73 | +0.44% | 11.5× |
| Humana | $385.47 | +1.74% | 36.4× |
| Risk | Transmission | Dashboard trigger |
|---|---|---|
| Commercial medical costs | Claims growth outruns pricing and delays margin recovery. | Trend stays above 11% into 2027. |
| Reserve quality | Q2 MCR benefited from $860M of favorable prior-period development. | Development fades or reverses. |
| Government programs | Medicare and Medicaid rate changes pressure margins or membership. | Reimbursement trails care-cost inflation. |
| Optum execution | A slower recovery weakens the earnings bridge supporting the multiple. | Optum margin stalls below the 6.2% Q2 level. |
Governance · Medicare · Cybersecurity
UNH is in focus after a derivative complaint alleged governance failures involving Medicare Advantage coding and the Change Healthcare breach. Any effect depends on court and regulatory outcomes. The allegations have not been adjudicated.
Filed August 7 in the U.S. District Court for Minnesota. No damages amount is stated.
CMS's final average 2027 Medicare Advantage payment increase. With estimated risk-score trend, it is 4.98%.
CMS will generally exclude diagnoses from unlinked chart reviews. UNH's 10-Q says coding reviews remain active.
| Date | Broker | Action | Rating | Target |
|---|---|---|---|---|
| Jul 21 | JPMorgan | Raised | Overweight | $516 |
| Jul 20 | Wells Fargo | Raised | Overweight | $526 |
| Jul 17 | Morgan Stanley | Raised | Overweight | $529 |
| Jul 17 | Goldman Sachs | Raised | Buy | $490 |
| Jul 17 | Oppenheimer | Raised | Outperform | $500 |
| Jul 17 | Bank of America | Raised | Buy | $512 |
| Jul 17 | UBS | Raised | Buy | $490 |
| Jul 16 | Baird | Upgrade | Neutral | $453 |
| Company | Price | Day | TTM P/E | 2026 guide multiple |
|---|---|---|---|---|
| UnitedHealth (NYSE:UNH) | $390.35 | -0.91% | 25.06x | 19.8x |
| Elevance (NYSE:ELV) | $399.74 | +0.37% | 17.70x | ≤14.8x |
| CVS (NYSE:CVS) | $94.02 | -0.94% | 24.81x | 11.8x |
| Cigna (NYSE:CI) | $279.56 | +0.38% | 11.57x | ≤9.2x |
| Humana (NYSE:HUM) | $377.07 | -1.29% | 35.61x | ≤41.9x |
Q2 operating earnings rose 55%, MCR improved 270 bp and guidance increased. Durable UnitedHealthcare and Optum margin gains would support the lower forward multiple.
The derivative allegations, DOJ and CMS reviews, Change Healthcare liabilities and renewed medical-cost pressure could weigh on expectations or sentiment.
